First Tracks reports positive Phase 1b celiac disease data
First Tracks Biotherapeutics said ANB033 produced significant histology and symptom benefits in Phase 1b celiac testing, with no serious adverse events reported.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
TradingView reported, citing an original First Tracks Biotherapeutics, Inc. press release distributed by GlobeNewswire, that the company had posted positive top-line results from Cohort 1 of a Phase 1b study of ANB033 in celiac disease. During a 14-day gluten challenge, the treatment showed statistically significant benefits over placebo in both histology and symptoms.
No serious adverse events were recorded, and the safety profile was described as favorable. The program has received FDA Fast Track designation, while a late-stage clinical trial is planned for 2027. The findings provide an early controlled human efficacy and safety signal for ANB033, although a larger and longer study will be needed to assess whether the results remain consistent.
why it matters
For markets, the data may reduce clinical uncertainty around the program and support its progression toward late-stage testing. Attention will shift to the trial planned for 2027 and to follow-up evidence on histology, symptoms and safety.
instruments
sources
- First Tracks Biotherapeutics (TRAX) Posts Positive Phase 1b Celiac Data — TradingView, 12 October 2026 at 11:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗